Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. More Details
+ 2 more risks
Flawless balance sheet and overvalued.
Share Price & News
How has Addex Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ADXN is more volatile than 90% of Swiss stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ADXN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
7 Day Return
1 Year Return
Return vs Industry: ADXN exceeded the Swiss Biotechs industry which returned 25.1% over the past year.
Return vs Market: ADXN exceeded the Swiss Market which returned 21% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Addex Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
2 months ago | Simply Wall StWhat Type Of Returns Would Addex Therapeutics'(VTX:ADXN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
4 months ago | Simply Wall StWe Think Addex Therapeutics (VTX:ADXN) Needs To Drive Business Growth Carefully
Is Addex Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ADXN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ADXN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ADXN is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: ADXN is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADXN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ADXN is good value based on its PB Ratio (3.1x) compared to the CH Biotechs industry average (6.2x).
How is Addex Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADXN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ADXN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ADXN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ADXN's revenue is expected to decline over the next 3 years (-33.6% per year).
High Growth Revenue: ADXN's revenue is forecast to decline over the next 3 years (-33.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ADXN's Return on Equity is forecast to be high in 3 years time
How has Addex Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADXN is currently unprofitable.
Growing Profit Margin: ADXN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ADXN is unprofitable, and losses have increased over the past 5 years at a rate of 41.6% per year.
Accelerating Growth: Unable to compare ADXN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADXN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5%).
Return on Equity
High ROE: ADXN has a negative Return on Equity (-88.01%), as it is currently unprofitable.
How is Addex Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ADXN's short term assets (CHF19.5M) exceed its short term liabilities (CHF3.6M).
Long Term Liabilities: ADXN's short term assets (CHF19.5M) exceed its long term liabilities (CHF2.0M).
Debt to Equity History and Analysis
Debt Level: ADXN is debt free.
Reducing Debt: ADXN had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADXN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ADXN has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 35.8% each year.
What is Addex Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ADXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADXN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ADXN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADXN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ADXN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Dyer (52 yo)
Mr. Timothy Mark Dyer, also known as Tim, has been Chief Executive Officer at Addex Therapeutics Ltd. since June 1, 2013. Mr. Dyer co-founded Addex Therapeutics Ltd. (also known as Addex Pharmaceuticals Lt...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD990.45K) is above average for companies of similar size in the Swiss market ($USD479.49K).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
Experienced Management: ADXN's management team is seasoned and experienced (5.2 years average tenure).
Experienced Board: ADXN's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.9%.
Addex Therapeutics Ltd's company bio, employee growth, exchange listings and data sources
- Name: Addex Therapeutics Ltd
- Ticker: ADXN
- Exchange: SWX
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF55.791m
- Shares outstanding: 34.02m
- Website: https://www.addextherapeutics.com
Number of Employees
- Addex Therapeutics Ltd
- Chemin des Mines, 9
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerla...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/09 17:09|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.